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Purpose of the study
Ritonavir/atazanavir has recently been registered for use
in antiretroviral naïve individuals requiring therapy. We
describe our experience of the use of ritonavir/atazanavir
in a large urban clinic population.
Methods
Retrospective case note review.
Summary of results
Between March 2004 and April 2008, 133 antiretroviral-
naïve individuals were commenced on ritonavir (100
mg)/atazanavir (300 mg) and two nucleos(t)ides. 103
commenced ritonavir/atazanavir with tenofovir and
emtricitabine or lamivudine, six with abacavir and lami-
vudine, and 24 with other nucleoside backbones. Mean
baseline viral load was 121,198 copies/ml and mean CD4
count was 221 cells/ml; 73 patients had a CD4 count
below 200 and 84 a viral load above 100,000. After 12
months of therapy, 79% had a viral load below 50 copies/
ml by ITT (intention to treat) and 89% by OT (on treat-
ment). With a viral load cut-off of less than 500 copies/
ml, 89% and 100% achieved this level by ITT and OT,
respectively. Mean CD4 count rise at 12 months was 202
cells/ml. There was no impact of baseline CD4 count or
viral load. 18 patients stopped therapy within 12 months.
Reasons for cessation of therapy were jaundice (eight),
simplification of therapy required (three) and not speci-
fied (seven). Mean rise in cholesterol at 12 months was
0.4 mmol/l.
Conclusion
Ritonavir/atazanavir is a safe and effective therapy in
antiretroviral-naïve individuals requiring a protease
inhibitor based therapy.
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